Oncotarget

Research Papers:

Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing

Soo Young Cho, Minhye Choi, Hyo-Jeong Ban, Chang Hyeon Lee, Soojun Park, HanKyeom Kim, Young-sik Kim, Young Seek Lee _ and Ji-Yun Lee

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:8095-8104. https://doi.org/10.18632/oncotarget.14098

Metrics: PDF 2207 views  |   HTML 4706 views  |   ?  


Abstract

Soo Young Cho1,*, Minhye Choi2,*, Hyo-Jeong Ban3,4,*, Chang Hyeon Lee5, Soojun Park6, HanKyeom Kim2, Young-Sik Kim2, Young Seek Lee3, Ji-Yun Lee2

1Laboratory of Developmental Biology and Genomics, College of Veterinary Medicine, Research Institute for Veterinary Science BK21, Program for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea

2Department of Pathology, College of Medicine, Korea University, Seoul 02841, Republic of Korea

3Division of Molecular and Life Sciences, Hanyang University, Ansan 15588, Republic of Korea

4Division of Bio-Medical Informatics, Center for Genome Science, National Research Institute of Health, Centers for Disease Control and Prevention, Choongchung-Buk-do 28159, Republic of Korea

5Life Science Solutions Group, Thermo Fisher Scientific Corporation, Seoul 06349, Republic of Korea

6Bio-Medical IT Research Department, ETRI, Yusoeng-gu, Daejeon 34129, Republic of Korea

*These authors have contributed equally to this work

Correspondence to:

Young Seek Lee, email: [email protected]

Ji-Yun Lee, email: [email protected]

Keywords: cervical small cell neuroendocrine tumor, ATRX, ERBB4, AKT/mTOR, whole exome sequencing

Received: July 18, 2016     Accepted: November 22, 2016     Published: December 22, 2016

ABSTRACT

Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14098